.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Queensland Health
Johnson and Johnson
Moodys
Citi
Accenture
Daiichi Sankyo
UBS
Cipla
Express Scripts

Generated: September 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 010104

« Back to Dashboard
NDA 010104 describes MEPHYTON, which is a drug marketed by Valeant Pharms and is included in one NDA. It is available from seven suppliers. Additional details are available on the MEPHYTON profile page.

The generic ingredient in MEPHYTON is phytonadione. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the phytonadione profile page.

Summary for NDA: 010104

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 010104

Suppliers and Packaging for NDA: 010104

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MEPHYTON
phytonadione
TABLET;ORAL 010104 NDA KAISER FOUNDATION HOSPITALS 0179-0133 0179-0133-70 30 TABLET in 1 BOX, UNIT-DOSE (0179-0133-70)
MEPHYTON
phytonadione
TABLET;ORAL 010104 NDA Valeant Pharmaceuticals North America LLC 0187-1704 0187-1704-05 1 BOTTLE in 1 CARTON (0187-1704-05) > 100 TABLET in 1 BOTTLE

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:Approved Prior to Jan 1, 1982TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
QuintilesIMS
Cipla
McKesson
Boehringer Ingelheim
UBS
Accenture
Federal Trade Commission
Cantor Fitzgerald
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot